Diagnosis and Main Criteria for Inclusion/Exclusion: Main Inclusion:
• Japanese male or female and age is between 18 and 75 years, inclusive, at time of screening.
• Chronic HCV infection at prior to study enrollment. Chronic HCV infection is defined as one of the following:
• Positive for anti-HCV antibody (Ab) or HCV RNA at least 6 months before Screening, and positive for HCV RNA and anti-HCVAb at the time of Screening; or • Positive for anti-HCV Ab and HCV RNA at the time of Screening with a liver biopsy consistent with chronic HCV infection at or prior to Screening.
• Patient has plasma HCV RNA level > 10,000 IU/mL at Screening.
• Patient must be:
Non-cirrhotic naïve patient, as defined as a patient who has never received any HCV treatment and meet one of the following categories;
• Naïve eligible patient will be defined as naïve patient who is considered by the investigator to be a good candidate to receive an IFN-based therapy [IFN (alpha, beta or pegIFN) with or without RBV]; or • Naïve ineligible patient will be defined as naïve patient who is considered by the investigator to be a poor candidate to receive an IFN-based therapy [IFN (alpha, beta or pegIFN) with or without RBV], due to medical reasons, such as, but not limited to, advanced age, depression, myelosuppression, diabetes, autoimmune disease, retinopathy or cardiovascular or renal dysfunction; OR Non-cirrhotic experienced patient, as defined as a patient who has documentation of prior IFN-based therapy [IFN (alpha, beta or pegIFN) with or without RBV] and meet one of the following categories:
• Nonresponder: received at least 12 weeks of IFN-based therapy for the treatment of HCV and failed to achieve undetectable HCV RNA (HCV RNA < LLOD) at the end of treatment; or • Relapser: received IFN-based therapy for the treatment of HCV and was undetectable at or after the end of treatment, but subsequently had detectable HCV RNA within 52 weeks of treatment follow-up; or • IFN Intolerant: treatment of HCV was discontinued during the treatment period due to intolerance to any of the components of the IFN-based therapy. OR Cirrhotic naïve patient, as defined as a patient who has never received any HCV treatment, OR Cirrhotic experienced patient, as defined as a patient who has documentation of prior IFNbased therapy [IFN (alpha, beta Patients with a FibroScan result that is ≥ 12.5 kPa and < 14.6 KPa; or a FibroTest result that is ≤ 0.72 and an APRI > 2; or a FibroTest result that is ≥ 0.73 and an APRI ≤ 2; or a Discriminant Score = 0, must have a liver biopsy performed within 24 months prior to screening showing no evidence of cirrhosis, or in the absence of an available biopsy result within 24 months prior to screening, may undergo a liver biopsy during screening to rule out cirrhosis. The result of the liver biopsy will be considered the decisive result for study eligibility and patients may be enrolled only if the biopsy performed within the previous 24 months or during the Screening period shows no evidence of cirrhosis.
• Patients enrolled in Substudy 2 will have cirrhosis, defined by the results of one of the following, performed according to local standard practice: Patients with a FibroScan result that is ≥ 12.5 kPa and < 14.6 KPa; or a FibroTest result that is ≤ 0.72 and an APRI > 2; or a FibroTest result that is ≥ 0.73 and an APRI ≤ 2; or a Discriminant Score = 0, must have a liver biopsy performed within 24 months prior to screening showing evidence of cirrhosis, or in the absence of an available biopsy result within 24 months prior to screening, may undergo a liver biopsy during screening to demonstrate the presence of cirrhosis. The result of the liver biopsy will be considered the decisive result for patient eligibility and patients may be enrolled only if the biopsy performed within the previous 24 months or during the Screening period shows evidence of cirrhosis.
• Patients enrolled in Substudy 2 will have compensated cirrhosis defined by a Child-Pugh score of ≤ 6 at Screening.
Main Exclusion:
• Positive test result at screening for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab).
• As per central clinical laboratory results, patient's HCV subgenotype at Screening is not subgenotype 1b, cannot be determined or indicates co-infection of subgenotype 1b with any other HCV genotype.
• Current enrollment in another clinical study, previous enrollment in this study, or previous use of any investigational or commercially available anti-HCV therapy (other than interferon (alpha, beta or pegIFN) with or without RBV) including previous exposure to telaprevir, boceprevir, simeprevir, ABT-450, ABT-267. 
Data imputation for HCV RNA endpoints
Missing data were imputed via a flanking imputation method, whereby the closest HCV RNA value before or after the study visit window was used. If a HCV RNA value at a post-baseline visit was missing, but the patient had an undetectable or unquantifiable HCV RNA level at both the preceding value and succeeding value, the HCV RNA level was imputed as undetectable or unquantifiable, respectively, at that visit. In addition, if the patient had an unquantifiable HCV RNA level at the preceding value and an undetectable HCV RNA level at the succeeding value, or vice versa, the HCV RNA level was imputed as unquantifiable at this visit. For SVR12 analyses, if there was no value in the appropriate window after the flanking imputation, a backward imputation approach was used such that if the nearest HCV RNA value after the SVR window was unquantifiable or undetectable, then it was used to impute the response in the SVR window. Patients with missing HCV RNA data in the analysis window after imputations were considered as failures.
Serious Adverse Events
Serious adverse events were defined as events that resulted in the death of the patient, were considered by the investigator to be life-threatening, resulted in hospitalization or prolongation of hospitalization, or resulted in persistent or significant disability/incapacity. Any important medical event requiring medical or surgical intervention to prevent serious outcome or any congenital anomaly was also considered a serious adverse event. 
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